文献速递前列腺癌

挽救性机器人辅助根治性前列腺切除术的多中心结局:EAU机器人泌尿外科工作组高容量数据

Outcomes of Salvage Robotic-assisted Radical Prostatectomy: High-volume Multicentric Data from the European Association of Urology Robotic Urology Section Scientific Working Group.
PubMed 文献 · Eur Urol · 2025-04-10

这项回顾性多中心研究纳入2008至2023年间9个中心接受挽救性机器人辅助根治性前列腺切除术(S-RARP)的397例患者,按先前治疗分为放疗(RT)、全腺体消融(WG)和局灶消融(FG)三组。S-RARP安全可行,围手术期并发症率低,但功能结局(控尿和勃起功能)低于初次手术,不同先前治疗组间肿瘤学结局无显著差异。

要点

  • S-RARP围手术期并发症率低,术中并发症仅1%,Clavien≥3级<2%。
  • 5年生化复发累积发生率RT组35%、FG组45%、WG组23%,组间无显著差异(p=0.3)。
  • 3年控尿累积发生率RT组67%、FG组92%、WG组71%,组间差异显著(p<0.001)。

核心结论

  • S-RARP安全可行,围手术期并发症率极低。
  • S-RARP后功能结局低于初次手术,需高超手术技术。
  • 应告知患者功能结局逊于初次手术。

研究设计与样本

  • 回顾性多中心研究,纳入欧洲泌尿外科学会机器人泌尿外科科学工作组9个中心2008至2023年397例接受S-RARP的患者。
  • 患者按先前治疗分为三组:放疗(RT)、全腺体消融(WG)和局灶消融(FG)。

主要发现

  • 中位随访时间:RT组38(19-73)个月,FG组20(10-37)个月,WG组24(16-38)个月(p<0.001)。
  • 术中并发症仅4例(1%),术后Clavien≥3级并发症<2%。
  • 5年生化复发累积发生率:RT组35%、FG组45%、WG组23%(p=0.3)。
  • 3年控尿累积发生率:RT组67%、FG组92%、WG组71%(p<0.001)。
  • 5年勃起功能累积发生率:RT组16%、FG组11%、WG组5.3%(p=0.2);5年总生存率:RT组95%、FG组94%、WG组100%(p=0.7)。

临床怎么用

  • S-RARP可用于前列腺保留治疗后复发患者,但需由高容量、高技能术者实施。
  • 术前应充分告知患者功能结局(控尿和勃起功能)低于初次手术。

局限性

  • 回顾性研究设计。
  • 不同先前治疗组随访时间存在显著差异(p<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Salvage robotic-assisted radical prostatectomy (S-RARP) is one option for treating patients with recurrent prostate cancer after prostate-preserving primary therapy. However, the tissue damage, anatomical distortion, and lack of surgical landmarks caused by the primary treatment still constitute a major challenge to surgeons. We aim to report the experience of our group on S-RARP. METHODS AND SURGICAL PROCEDURE: A retrospective multicentric study including data from nine centers from the European Association of Urology Robotic Urology Section Scientific Working Group was conducted. Overall, 397 patients who underwent S-RARP from 2008 to 2023 were included and divided into three groups (primary radiation therapy [RT], whole gland [WG] ablation, and focal gland [FG] ablation). The primary endpoints were the safety and feasibility of S-RARP. The secondary endpoints were the comparison of functional and oncological outcomes among different primary therapies. KEY FINDINGS AND LIMITATIONS: The median (interquartile range) follow-up periods for RT, FG ablation, and WG ablation were 38 (19-73), 20 (10-37), and 24 (16-38) mo, respectively (p < 0.001). Only four patients (1%) had intraoperative complications and <2% had Clavien grade ≥3 after surgery. The 5-yr cumulative incidence rates of biochemical recurrence were 35%, 45%, and 23% for RT, FG ablation, and WG ablation, respectively (p = 0.3). The 3-yr cumulative incidence rates of continence were 67%, 92%, and 71% for RT, FG ablation, and WG ablation, respectively (p < 0.001). The 5-yr cumulative incidence rates of potency were 16%, 11%, and 5.3% (p = 0.2), while the overall survival rates at 5 yr were 95%, 94%, and 100% for RT, FG ablation, and WG ablation, respectively (p = 0.7). CONCLUSIONS: S-RARP is safe and feasible with very low rates of perioperative complications. Functional outcomes in patients undergoing S-RARP are inferior to outcomes at primary surgery and demand highly skilled surgical expertise. Patients should be counseled carefully that the functional outcomes are inferior to those at primary surgery.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Covas Moschovas M, Saikali S, Sandri M, et al. Outcomes of Salvage Robotic-assisted Radical Prostatectomy: High-volume Multicentric Data from the European Association of Urology Robotic Urology Section Scientific Working Group. Eur Urol. 2025. PMID: 40210552. doi:10.1016/j.eururo.2025.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。